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INTRODUCTION 
 
Chronic Obstructive Pulmonary Airway Disease is a Preventable & 
Treatable Disease which is characterised by irreversible  airflow 
limitation  of  progressive in nature  occurring  due to chronic 
inflammatory response affecting the  lung parenchyma  &  airways to 
noxious stimulants& various toxic pollutants  in the  atmosphere. The 
Global Burden Of Disease Society States that COPD will become the 
“THIRD” leading cause of death by 2020. COPD is a chronic systemic 
disease affecting the  vital organ systems in the body,  since  it is not 
confined to affect only the respiratory system.  COPD often leads to 
Anaemia, Osteoporosis,  Ischemic Heart Disease, Muscle Wasting , 
Depression & various  other systemic ailments. 
Extrapulmonary  effects of COPD often culminates in significant 
morbidity & mortality which affects the quality of life in the COPD 
individuals. Endocrinological disorders occurs in COPD as a result of 
Hypoxia, Hypercapnia, Iatrogenic usage of Glucocorticoids, Systemic 
inflammatory mediators such as IL 6, INF gamma,Tumour necrosis factor 
alpha , IL 1. Among the Endocrinological  disorders , Thyroid disease is 
quite common among COPD individuals. 
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Thyroid hormone has vital role  in metabolism of carbohydrates , 
proteins,  lipids, membrane bound enzymes & regulation of 
thermogenesis. As the severity of COPD increases, impaired Thyroid 
function in the form of  Sub Clinical Hypothyroidism, Overt 
Hypothyroidism, Nonthyroid Illness Syndrome can   manifest. 
Hypothyroidism adversely affect the quality of life in COPD individuals. 
Hypothyroid in COPD leads to decreased respiratory drive, Acute 
on chronic alveolar hypoventilation, Decreased lung volumes, Depression 
of  respiratory centres to its stimulants, Upper airway obstruction, 
Respiratory Failure & frequent exaceberations. Hypothyroidism causes  
inspiratory & expiratory muscle weakness due to impaired expression of 
myosin heavy chains IIb & decreased neuromuscular transmission. 
Diaphragmatic dysfunction &  myopathy can occur. Severity of  
hypothyroidism linearly correlates with muscle weakness & myopathy. 
All these factors results in frequent exaceberations of COPD  which  has 
significant role in affecting the quality of life in COPD individuals. 
Hence, determining the functional state of Thyroid gland is of remarkable 
importance in treatment of COPD. 
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AIMS & OBJECTIVES 
 
 To assess the prevalence of Thyroid dysfunction in moderate to 
severe  COPD patients. 
 To measure the relationship between COPD severity with the 
Thyroid function abnormality. 
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REVIEW OF LITERATURE 
 
Chronic Obstructive Pulmonary Disease Is characterised by 
progressive development of chronic air flow limitation which is not fully 
reversible as defined by GOLD (Global Initiative Of Obstructive Lung 
Disease). COPD is a preventable & treatable disease as well . COPD 
includes  two broad categories which are Chronic Bronchitis and 
Emphysema. By definition, Chronic Bronchitis is characterized by 
chronic cough with expectoration for more than three months in two 
consecutive years . Emphysema is described  as abnormal persistent  
distension of the air spaces  distal to the terminal bronchioles associated 
with destruction of their walls without any obvious fibrosis. 
Epidemiology 
In India, COPD being the second most common lung disorder 
successive to the Pulmonary Tuberculosis.   Its incidence is encountered 
mainly in the fourth decade. It has an equal incidence among people 
living in  rural and urban areas. COPD manifestation is usually rare 
below the age of 35 years of age.  
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Risk factors 
1) Tobacco smoking  
2) Air pollution – Indoor & Outdoor Pollutants 
3) Familial and Genetic factors 
4) Recurrent Respiratory Tract Infections in childhood 
5) Occupational hazards due to inhalation of  noxious particlulates -  
organic or  Inorganic dust fumes. 
 Tobacco smoking  
“It is the most predominant risk factor associated with a 
progression of COPD”. It mainly contains vapourised chemicals, serious  
noxious particulates, carcinogens  which are suspended in the gaseous 
medium. Tobacco smoked is directly proportional to the detrimental 
effects observed in COPD patients. Pack years,   smoking index are the 
most vital  parameters which are used for categorizing the smoking 
exposure and possibility of the disease outcome. 
Sustained and chronic cigarette smokers are more susceptible  to 
impaired ciliary motility, goblet cell hyperplasia with its tenacious 
secretions due to  hypertrophy of the respiratory secretory epithelium. 
Reid index is often used as a pathological index used to assess the 
severity of the Chronic Bronchitis. It is the ratio between the thickness of   
mucus gland to  the complete  wall thickness which is between the 
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cartilage and the epithelium. (Normal =  0.44). Passive smoking and 
inhalation of environmental noxious particulates resulted in the 
deterioration of  pulmonary function. But their role in the manifestation 
of COPD still being  uncertain. 
Pack years:       
Number of packets of                  x         Numbers of years of 
Cigarettes smoked per day              Smoking 
 
Smoking index:  
Number of cigarettes                  x Number of years of 
Smoked per day                                         Smoking 
Air pollution 
Due to urbanisation, industrialized urban areas are loaded with 
COPD patients. The heavy air pollutants includes mainly sulphur dioxide 
and wooden logs used for cooking, indoor pollution made by burning of 
cow dung cakes all contributing significantly to atmospheric pollution . 
Occupational hazards 
COPD is more prevalent among people who were working in 
places  where organic or inorganic or noxious pollutants  are enriched in 
the atmosphere. 
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Recurrent respiratory infection in childhood 
Precipitating infections are the main culprit factors  for acute 
exacerbation in  chronic background of obstructive pulmonary airway 
disease. It is the  factor which resulted in a significant increase in the 
morbidity and mortality. Release of proteolytic enzymes such as 
Metalloproteinases, Serinase, Lysosomal enzymes  from the first line 
defence mechanism cells - Neutrophils contributes to the extensive lung 
pathology. Recurrent  Viral respiratory tract  infections during the infancy 
period is pivotal  in causing airway obstruction in the later life 
Genetic mechanism 
Randomised control Studies have suggested monozygotic twins are 
prone to develop emphysema & chronic bronchitis due to genetic 
predisposition. 
Alpha 1 Antitrypsin is a serine protease inhibitor & an  acute phase 
reactant.  Alpha 1 Antitrypsin deficiency in COPD patients is one to two 
percent . The deficiency level rises to 50 percent in  severe monozygotic 
diseased people which usually affects younger age group. Alpha 1 
antitrypsin inhibits elastase, collagenase and  other proteolytic  enzymes 
& offers  protection to  lung in clearing the secretions. Alpha 1 antitrypsin 
deficiency is the strongest genetic factor in development of chronic 
obstructive pulmonary disease especially Emphysema. Emphysema 
8 
 
predominantly involve lower lobes , which is usually pan lobular or pan 
acinar but in smokers it affects the upper lobe and it is of centri lobular or 
centri acinar type. Protease inhibitors variants that encode alpha 1 
antitrypsin have been recognized. Two alleles such as S & Z alleles are 
associated with reduced and markedly reduced alpha 1 antitrypsin levels 
respectively.  
Treatment with Alpha 1 Antitrypsin enzyme augmentation therapy 
is available in recent times with linkage analysis of earlier onset disease 
among family members have evidenced various spirometric variations 
linked to appropriate regions of the chromosomes. Determinants of 
specific genetic coding regions yet to be identified 
Acute exacerbation precipitating factors  
 Infections - Streptococcus pneumonia, Haemophilus influenza, 
Moraxella catarrahalis , Chlamydia pneumoniae 
 Exposure to noxious stimulants 
 Pneumothorax 
 Pulmonary thromboembolism, Myocardial infarction 
Pathology of COPD 
In the entity of  Chronic Bronchitis, there is hypertrophy of goblet 
cells  which secrete mucus in the respiratory epithelium. In COPD 
airways , Inflammatory cells mainly  Neutrophils accumulate in the sub 
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mucosal  and the mucosal regions of the  epithelium. Fibrosis involving 
the peribronchus &  accumulation of mucus plug in the intralumen of the 
bronchus also contributes to the COPD pathology . 
Emphysema is categeorized   according to the involvement of 
airway  distal to the terminal bronchiole. Panacinar  signifies the 
involvement of whole acinus involving central and peripheral portions. In 
centriacinar involves the  respiratory bronchioles without involving the 
periphery. An entity known as paraseptal involving the airspaces at the 
lobule periphery nearer to the pleura.  Irregular pattern almost associated 
with scarring occurs in post pulmonary tuberculosis. 
Pathophysiology of COPD 
Two determinants of COPD as Chronic Bronchitis and  
Emphysema  often  frequently coexist each other & there may be 
domination of one entity  over the other. Narrowing of the airway is a 
common pathology in both categories. Besides basic pathophysiology of 
the airways, there is  loss of  elastic recoiling capacity of lung  
parenchyma in Emphysema leads to  poor radial support to airways. 
Increased work of breathing experienced by COPD patients is due to 
alteration in the pressure and airflow pattern. Spirometry helps to 
determine the major pulmonary  functional  parameters such as FVC and 
FEV1. In COPD patients, alteration in the FEV1/FVC ratio and reduction 
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in the FEV1 contributes towards the major morbidity. Responsiveness to 
the inhaled bronchodilators is maximum in  COPD  as compared to 
Bronchial asthma. Imbalance between the elastic recoil of the alveolar sac 
and resistance offered by the airway towards the airflow determines the 
reduction in FEV1 and FEV1/FVC. Residual volume and increase in the 
ratio of residual volume to total lung capacity, is mainly due to trapping 
of air. Total lung capacity is increased resulting in hyperinflation of lung 
which is one of the late manifestations of COPD. Hyperinflation 
preserves airflow during peak expiration. It is due to increase in the lung 
volume which increases the elastic recoiling pressures & leading to  
enlargement of airway thereby  decreasing the resistance of the airways. 
Hyperinflation is the compensatory mechanism to relieve the airway 
obstruction. However flattened position of the diaphragm resulted in the 
various adverse effects. The opposition zone between the abdominal wall 
and diaphragm is decreased,  effective abdominal pressure during 
inspiration to the chest wall is not applied. Abnormal movement due to 
hindering rib cage  impairs the inspiration.Muscle fibers of the flattened 
diaphragm are abnormally shorter than the normal diaphragm, resulting in 
the less capability of inspiratory pressures. 
                        According to Laplace‟s law ,  
   P=2T/R 
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P = Trans pulmonary pressure producing the tidal breathing. 
T = Tension gradient of the flattened diaphragm 
R = Radius of the curvature 
The flattened diaphragm has to generate tension to overcome the 
trans pulmonary pressure to generate normal tidal volumes. In COPD, 
partial pressure of O2 is not altered until FEV1 falls to 50%. Cardiac 
complications like  Pulmonary hypertension, Right heart failure, 
CorPulmonale  occurs when  FEV1 is  less than 25% of predicted value  
with reduction in the partial pressure of oxygen to less than 55 mm of hg. 
Mismatch between perfusion-ventilation & disproportionate ventilation 
are the penultimate features of COPD. It reflects the diverse pathological 
abnormality within the parenchyma & the smaller bronchi. 
Pathogenesis 
Airflow limitation is  due to obstruction in the smaller airways and 
Emphysema is the major pathological sequeale in COPD. Smaller 
airways surrounded by fibrosis contributes significantly to morbidity and 
mortality. Collagenase activity increases during the pathogenesis in 
COPD. It is the major culprit resulting in accumulation of collagen 
surrounding the airway. Potential mechanism through which fibrosis is 
induced by activation of fibrogenic cytokines by growth factors such as 
TGf -β. In Emphysema pathogenesis is mainly due to recruitement of 
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inflammatory cells in the distal air spaces due to chronic exposure to 
cigarette smoke. These cells damage the matrix of the lung parenchyma 
by releasing more potent proteinases like Elastases. The interaction 
between cell and the matrix is lost,  resulting in the apoptosis of the 
structural cells in the lung. Extracellular matrix forms a integrity between 
smaller airways & lung parenchyma. It is offered mainly by elastin a 
predominant component of elastic fibers. The imbalance between 
degrading enzymes and inhibitors involved in Elastin biology determines 
the abnormal permanent distension of air spaces. Alpha 1 antitrypsin 
deficiency patients are more prone for Emphysema due to lack of  
neutrophil elastase inhibitor . Inactivation of histone deacetylase2 
resulted in the acetylation and more heterochromatin which exposes the 
transcription sites involving many pro inflammatory cytokines resulting 
in recruitment of Neutrophils. Cigarette smoke recruits the suppressor 
Tcells leading to production of macrophage elastase. Cleavage 
component of elastin acts as a signaling chemokine which traverse the 
destructive hypothesis. Ciliary dysfunction caused by cigarette smoke 
traverse the fertile background for bacterial infection along with increase 
in Neutrophill count. In final stage, there is an copious  inflammatory 
response suggesting that mechanisms of smoking induced disease differs 
from inflammation resulting after cessation of smoking.. Finally the 
collagen content profusely increased  in  the smaller airways. By 
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degrading the matrix of lung parenchyma with defect in the cell 
anchoring leads to apoptosis. Reparative capacity of the damaged alveoli 
remains questionable. 
Potential stimulus for constriction of pulmonary vasculature is 
hypoxia. Cross sectional area of pulmonary vasculature is reduced in 
COPD patients due to alteration in the vascular smooth musculature of 
artery &  arteriole of pulmonary vessels. Acidosis and the polycythaemia 
due to chronic hypoxia culminates in right heart failure. 
Clinical features 
Chronic bronchitis 
Cough along with sputum production forms the mainstay of 
Chronic  bronchitis. History of chronic smoking is always present. 
Predominant cough during winter months is the earlier manifestation. 
Increase in the frequency of bronchial infection favours chronic 
bronchitis. Insufficient respiration occurs during acute exacerbation. 
Prominent bronchovascular markings is of  pathognomic feature in 
chronic bronchitis variant of  COPD. 
Over weight and cyanosis picture favours the terminology „blue 
bloaters‟. Crepitation and polyphonic wheeze with resonant lung is 
always  associated. Incidence  blood gas derangements such as hypoxia 
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resulting in polycythaemia is common. Pulmonary vascular pathology 
and right sided heart failure are more prevalent in chronic bronchitis. 
Emphysema 
History of dyspnoea with minimal cough and scanty production of 
sputum is the main clinical feature of Emphysema. The Asthenic body 
build with evidence of loss of weight noted in the physical examination. 
The predominant usage of accessory muscles involved in respiration 
resulted in sternal lift in anterosuperior direction in each phase of 
inspiration. Tachypnea with prolonged expiratory phase through pursed 
lip is characteristic of emphysema. Leaning forward with extension of his 
arms to brace himself in sitting posture is known as tripod position. The 
intercostals spaces retract each other during each inspiration in the lower 
region of hemithorax which can be felt by palpation is known as 
Hoover‟s sign. Apical impulse is usually visualized in the region between 
xiphoid and subxiphoid areas. Hyperresonant percussion note with absent 
or reduced cardiac dullness is a classical feature seen in COPD. The 
upper margin of liver is usually shifted to a lower level than the normal. 
Added sounds and abnormal air entry makes the clue to differentiate from 
normal variant – compensatory emphysema. Since partial pressure of 
oxygen is maintained in emphysema, they are called as pink puffers. 
Gallop rhythm during pre systole of the cardiac cycle is accentuated in 
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the inspiratory phase of the respiration. Since inflammatory cytokines 
such as tumor necrosis factor alpha is elevated resulting in malnutrition 
which is manifested as muscle wasting and it is an independent poor 
prognostic variable in COPD. Incidence of right sided heart failure and 
pulmonary hypertension is rare among emphysematous patients due to  
maintenance in the partial pressure of oxygen in normal range. Diffusing 
capacity with carbon monoxide used to differentiate chronic bronchitis 
and emphysema decreased in emphysema and normal or slight variation 
in chronic bronchitis. Advanced disease is manifested in form of 
universal wasting more predominantly in bitemporal areas. Digital 
clubbing is usually not a significant finding in COPD. Its presence should 
warrant an alternate pathology in lung parenchyma. 
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COPD assessment 
It requires a confined stratification taking into account of all the 
factors. Four groups have been stratified by GOLD guidelines 
 Group A - low risk, less symptoms 
 Group B - low risk, more symptoms 
 Group C - high risk, less symptoms  
 Group D - high risk, more symptoms 
Stage 3 or 4 with airflow limitation assessed by Spirometry is 
given a label of high risk. Acute exacerbations more than 2 in no in the 
previous year are hospitalisation requiring exacerbations are also taken 
into account. 
Symptoms are mainly assessed by  
 COPD Assessment test 
 COPD Control questionare 
 Chronic Respiratory Questionare. 
 St George Respiratory Questionare. 
Parameters which predicts the prognosis involves BODE Index 
B  Body Mass Index 
O  Obstruction( Assessed by Spirometry) 
D  Dyspnoea 
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E Exercise tolerance 
     GOLD CLASSIFICATION OF COPD BY SPIROMETRY  
STAGES        CHARCTERISTICS 
      (POST BRONCHODILATOR  
     RESPONSE)    
Mild     FEV1 / FVC ≤ 70%, FEV1 > 80% 
Moderate    FEV1 / FVC ≤ 70%, FEV1 50-80% 
Severe    FEV1 / FVC ≤ 70%, FEV1 30-50% 
Very Severe   FEV1 < 30% PREDICTED (OR)                                              
     FEV1 <50% PREDICTED WITH  
     RESPIRATORY FAILURE    
Spirometry  
Staging of COPD have been classified in similar manner from mild  
to very severe COPD.  FEV1/FVC ratio of < 0.7 is also applicable. FEV1 
is the main predictor in COPD staging. 
Comorbidities  
 Cardio vascular disorders 
 Skeletal muscle dysfunction 
 Nutritional deficiencies 
 Endocrine Disorders - Hypothyroidism 
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 Depression 
 Metabolic Syndrome 
 Osteoporosis 
 Cachexia  
 Lung malignancies 
 Hypercarbia related complications 
Investigations used in diagnosing COPD 
Spirometry – Pulmonary Function Test 
Spirometry is the most commonly used lung function screening 
study. It generally should be the clinician's first option, with other studies 
being reserved for specific indications. Most patients can easily perform 
spirometry when coached by an appropriately trained technician or other 
health care provider. The test can be administered in the ambulatory 
setting, physician's office, emergency department or inpatient setting. 
“The indications for spirometry are diverse” .Spirometry requires a 
voluntary manoeuvre in which a seated patient inhales maximally from 
tidal respiration to total lung capacity and then rapidly exhales to the 
fullest extent until no further volume is exhaled at residual volume. “The 
manoeuvre may be performed in a forceful manner to generate a forced 
vital capacity (FVC) or in a more relaxed manner to generate a slow vital 
capacity (SVC). In normal persons, the inspiratory vital capacity, the 
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expiratory SVC and expiratory FVC are essentially equal. However, in 
patients with obstructive small airways disease, the expiratory SVC is 
generally higher than the FVC. 
This difference might, however, be due partly to the difficulty in 
maintaining a maximum expiratory effort for an extended time period 
without experiencing dizziness or light headedness. 
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The Spirometer can measure only the lung volumes that the subject 
can exchange with it. As is the case with many pulmonary function tests, 
the subject must be conscious and cooperative and understand the 
instructions for performing the test. The VT, IRV, ERV, IC, and VC can 
all be measured with a Spirometer (as can the Forced Expiratory Volume 
in 1 second [FEV1], Forced Vital Capacity [FVC] and Forced Expiratory 
Flow [FEF25–75%]). The RV, FRC, and the TLC cannot be determined 
with a spirometer because the subject cannot exhale the lungs completely. 
The gas in a spirometer is at ambient temperature, pressure and water 
vapour saturation and the volumes of gas collected in a spirometer must 
be converted to equivalent volumes in the body. Other kinds of 
spirometers include rolling seal and bellows spirometers. These 
spirometers are not water-filled and are more portable. 
“A spirogram is a graphic representation of bulk air movement 
depicted as a volume-time tracing or as a flow-volume tracing. Values 
generated from a simple spirogram provide important graphic and 
numeric data regarding the  mechanical properties of the lungs including 
airflow (Forced Expiratory Volume in 1 second [FEV1] along with other 
timed volumes) and exhaled lung volume (FVC or SVC). The 
measurement is typically expressed in liters for volumes or in liters per 
second for flows and is corrected for body temperature and pressure of 
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gas that is saturated with water vapour. Data from a spirogram provide 
important clues to help distinguish obstructive pulmonary disorders that 
typically reduce airflow  such as asthma and emphysema, from restrictive 
disorders that typically reduce total lung volumes including pulmonary 
fibrosis and neuromuscular disease” 
 
Forced Expiratory Volume in 1 Second 
“The FEV1 is the most widely used parameter to measure the 
mechanicalproperties of the lungs. In normal persons, the FEV1 accounts 
for the greatestpart of the exhaled volume from a spirometric maneuver 
and reflects mechanical properties of the large and the medium-sized 
airways. In a normal flow-volume loop, the FEV1 occurs at about 75% to 
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85% of the FVC. This parameter isreduced in obstructive and restrictive 
disorders. In obstructive diseases, FEV1 is reduced disproportionately to 
the FVC, reducing the FEV1/FVC ratio below the lower limit of normal 
and indicates airflow limitation. In restrictive disorders, the FEV1, FVC,  
and total lung capacity are all reduced, and the FEV1/FVC ratio is normal 
or even elevated.” 
Forced Vital Capacity 
FVC is a measure of lung volume and is usually reduced in 
diseases that cause the lungs to be smaller. Such processes are generally 
termed restrictive and can include disorders of the lung parenchyma such 
as pulmonary fibrosis or of the bellows, including kyphoscoliosis, 
neuromuscular disease, and pleural effusion. However, a reduction in 
FVC is not always due to reduced total volumes and can occur in the 
setting of large lungs hyperinflated due to severe airflow obstruction and 
air trapping, as in emphysema. In this setting, the FVC is decreased due 
to reduced airflow, air trapping, and increased residual volume, a 
phenomenon referred to as pseudo restriction. Reduced FVC can occur 
despite a normal or increased total lung volume. Therefore, FVC is not a 
reliable indicator of total lung capacity or restriction, especially in the 
setting of airflow obstruction. The overall accuracy of the FVC for 
restriction is about 60%” 
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FEV1   Forced Expiratory Volume in 1 second 
LLN     Lower limit of normal 
TLC     Total lung capacity 
VC  Vital Capacity 
Adapted from American Thoracic Society: Lung function testing: 
Selection of reference values and interpretative strategies.  
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Measurement of Lung Volumes not measurable with Spirometry. 
The Residual Volume (RV), Total Lung Capacity (TLC) and related 
volumes cannot be measured directly so special techniques are required to 
record these volumes. There are several accepted methods for 
determining these volumes, which are frequently referred to as 'static lung 
volumes'. These methods include helium dilution, nitrogen washout and 
body plethysmography.  The FRC is usually determined and RV (which 
is equal to FRC minus ERV) and the TLC (which is equal to VC plus 
RV) are then calculated from volumes obtained by spirometry. 
Nitrogen-Washout Technique 
In the nitrogen-washout technique, the person breathes 100% 
oxygen through a one-way valve so that all the expired gas is collected. 
The concentration of nitrogen in the expired air is monitored with a 
nitrogen analyzer until it reaches zero. At this point all the nitrogen is 
washed out of the person's lungs. The total volume of all the gas the 
person expired is determined, and this amount is multiplied by the 
percentage of nitrogen in the mixed expired air, which can be determined 
with the nitrogen analyzer. The total volume of nitrogen in the person's 
lungs at the beginning of the test can thus be determined. Nitrogen 
constitutes about 80% of the person's initial lung volume, and so 
multiplying the initial nitrogen volume by 1.25 gives the person's initial 
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lung volume. If the test is begun at the” end of a normal expiration, “the 
volume determined is the FRC. 
Total Volume expired X %N2 = original volume of N2 in the lungs 
original volume of N2 in the lungs X 1.25 = original Lung Volume 
2) Imaging   
 Xray  
 Bronchial wall thickening  manifested by tramline Shadows 
with     dominant  
 broncho vascular markings suggest chronic bronchitis. 
 Hyperlucent lung fields with no peripheral vascular 
markings, emphysematous bullae, low level diaphragm, 
tubular heart suggest Emphysema. 
 HRCT - Dilated main pulmonary artery and its branches is more 
prominent when COPD progresses towards cor pulmonale  
 DLCO - diffusion lung capcity carbon monoxide 
 12 leads electrocardiogram 
 2D Echocardiography 
 Sputum examination 
 Alpha1 antitrypsin level 
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Complications of COPD 
 Pneumothorax 
 Pulmonary artery hypertension 
 Polycythemia 
 Cor Pulmonale 
 Acute and chronic on chronic respiratory failure 
 Right sided heart failure 
 Recurrent episodes of acute exacerbations 
Potential markers used in prognosis of COPD 
 Alpha 1 antitrypsin deficiency 
 CFTR gene mutation 
 MBI2 genes 
 Fibrinogen, C reactive protein and other acute phase reactants 
during exacerbation. 
Potential measures to reduce the mortality in COPD can be reduced 
by following measures by 
 Cessation of smoking 
 Long term domiciliary oxygen therapy 
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Smoking cessation 
Pharmacological measures  
Nicotine Replacement Therapy - Transdermal patch, chewing 
gums, lozenges, inhalers, nasal spray. 
Non Nicotine pharmacotherapy: 
Bupropion 150 mg per day * 3 days followed by bd * 7 – 12 
weeks. 
Drug Should be started 1 week before quit date. Adverse effects  
are dizziness, headache, insomnia ,nausea, xerostomia, hypertension, 
seizures.  
Avoid monoamine oxidase inhibitors to prevent serotonin 
syndrome. 
Varenicline 0.5 mg per day * 3 days followed by BD * 4 days ,then 
1 mg BD * 12-24 weeks .start 1 week before quit date. 
Domiciliary oxygen therapy 
There are three forms of domiciliary supplementary oxygen 
therapy, 
 Long term control oxygen therapy for atleast 15 hours daily in 
patients with Chronic respiratory failure. 
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 In exercise related hypoxemia portable oxygen therapy is 
supplemented. 
 Short term and short burst oxygen therapy as a palliative treatment 
for temporary relief . 
Criteria for long term oxygen therapy 
“Absolute indications –  COPD ,  Hypoxemia , Edema , FEV1 < 
1.5 l , FVC <2l , Pao2 < 55 mm hg , PaCo2 > 45 mm hg , P pulmonale > 
3 mm in Lead II, III, avf, Pulmonary Hypertension , Cor Pulmonale , 
Right ventricular hypertrophy, Polycythemia with Erythrocytosis with 
hematocrit > 56% , desaturation < 96% on exercise , refractory dyspnea 
associated with cardiac failure. Relative indications – as mentioned above 
but without Edema or Paco2 >45mm hg”. 
Palliative 
FEV1 is the strongest predictor of survival in long term oxygen 
therapy. It has been shown to affect the polycythemia which occurs 
during chronic hypoxemia. It reduces both hematocrit and red cell mass. 
However with persistent smoking exposure which results in chronic 
elevation of carboxy hemoglobin decreases the effectiveness of long term 
oxygen therapy in correcting  polycythemia. It showed a marked decrease 
in pulmonary artery Pressure with breathing controlled oxygen therapy. It 
provides an evidence of improvement in cognitive function with little 
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change in mood or quality of life. It showed a sustained improvement in 
exercise endurance in patients with COPD breathing supplemental 
oxygen. It is also associated with improvement in the sub maximal work 
rate, with improvement in walking distance and ability to perform daily 
activities .with 6 months of long term oxygen therapy, there is a 
remarkable reduction in the mortality associated with COPD. 
Long term management in COPD 
Bronchodilator therapy is the treatment to reduce the symptoms 
and improves the  exercise capacity in COPD. The principle symptomatic 
bronchodilators can be divided into three groups based on their 
pharmacological properties. 
1.Inhaled beta 2 agonists are preferred over oral preparations. It showed 
significant improvement in bronchodilation.in chronic bronchitis & the 
decline in FEV1 was more reduced  in those patients who used 
continuous beta 2 agonists. However bronchodilator benefits are less 
compared to asthma due to structural damages in airways. 
2.Anticholinergics have time to peak effect of 30 to 60 minutes in most 
COPD patients , which is slower than beta 2 agonists but have a 
somewhat longer time of effectiveness of 6 to 10 hours compared with 
beta 2 agonists. There is a conflicting evidence regarding the effects of 
“Ipratropium Bromide” on exercise in patients with COPD. It showed an 
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increase in maximum exercise, ventilation and reduction in oxygen 
consumption at any given workload. 
3. Theophyllines 
The bronchodilator property of theophyllines is relatively limited 
in patients with COPD. Non bronchodilator effects of theophyllines such 
as improving right ventricular performance and their anti inflammatory 
actions are of questionable clinical significance. It has a narrow 
therapeutic index with experienced side effects.theophylline metabolism 
is increased by cigarette smoking , anti convulsant drugs , rifampicin. 
Decreased by congestive cardiac failure , respiratory acidosis , liver 
cirrhosis , viral infection , old age, arterial hypoxemia , on drugs like 
erythromycin , ciprofloxacin , Cimetidine.  
4. Glucocorticoids 
Chronic inflammation in large and small airways is a characteristic 
feature of COPD. The use of corticosteroids in COPD remains 
contentious particularly the prediction of which patients will respond to 
this treatment. 
5. Pulmonary Rehabilitation 
The restoration of the individual to the medical , emotional , social 
and vocational potential of which he/she is capable. The main aim of 
rehabilitation is to prevent the deconditioning that occurs with lack of 
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exercise and immobility due to dyspnea and allow the patient to cope 
with the disease. Exercise training programmes have taken two 
approaches the first is to attempt to improve cardiorespiratory fitness by 
aerobic exercises of 20 to 30 minutes duration atleast three times per 
week. It has been suggested that due to training effect ,it is usually 
restricted to those patients with mild to moderate exercise limitation. 
Second approach is to improve their Anaerobic fitness. In patients with 
very severe COPD, there are no established guidelines for pulmonary 
rehabilitation programmes, but carefully supervised exercise condition in 
the hospital setting , with oxygen supplementation should be considered 
in those who develop hypoxemia during exercise. Respiratory muscle 
training and ventilatory assist devices have been used to reduce the 
ventilator limitation during exercise. The presence of resting hypercarbia 
is not a contraindication to pulmonary rehabilitation. Education of 
patients in understanding the various components of the disease is 
intuitively valid. Mood disturbance particularly depression are very 
common in patients with advanced disease. 
Exercise training 
Expiratory flow rates during tidal breathing in patients with severe 
COPD are close to the maximum expiratory flow volume relationship. An 
increase in expiratory flow rate can occur during exercise in patients with 
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COPD through dynamic hyper inflation.at the expense of increase in 
respiratory work , since tidal volume operates in a less compliant range of 
the pressure volume relationship and hence initiation of inspiration 
requires additional inspiratory pressures to overcome elastic recoiling of 
the diseased airways Continuous positive airway pressure overcomes the 
increased recoil Pressure at the end of expiration , thus reducing breathing 
workload. 
Controlled breathing techniques 
It attempts to diminish the breathlessness by training the  patients 
to breath efficiently. It mainly aims for  
 Restoration of diaphragm to a more normal position and function. 
 Decrease the respiratory rate by using a breathing pattern that 
diminishes air trapping, Improving  the respiratory duty cycle. 
 To diminish breathing workload. 
 To reduce dyspnea and alleviate patient anxiety. 
The effects of different postures on respiratory muscle function 
have also been assessed. Diaphragmatic breathing exercises have been 
used to improve diaphragm function and are thought to be most helpful in 
patients with hyperventilation. 
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Nutrition 
Weight loss ( Cachexia) is common in COPD patients particularly 
those with severe airway obstruction. Those patients with less than 90% 
of their ideal body weight are generally considered to be malnourished. 
Weight loss has been associated with a higher mortality in these patients, 
it would therefore seem logical to give nutritional support to patients with 
COPD. The weight gain is lost soon after cessation of nutritional support 
and any improvement in Peripheral muscle performance and exercise 
capacity are also small and of short duration. However if sustained weight 
gain can be achieved this may improve survival.& the theoretical 
complication of carbohydrate based diet increasing carbondioxide 
production and hence hypercapnia in patients with COPD  does not 
appear to be a problem. Obesity should be discouraged in patients with 
COPD in order to avoid additional strain on the cardiorespiratory system 
& appropriate dietary advice should be given.  
Vaccination 
Influenza & Pneumococcal vaccination are recommended for 
patients with COPD, although the specific evidence for this in COPD 
patients is lacking. 
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Lung transplantation 
Indications 
 Age<50 years for heart-lung transplantation or double lung 
transplantation 
 Age<60 years for single lung transplantation 
 Patients with an estimated life expectancy of less than 18 months 
Contraindications  
 Malnutrition is a relative contraindication 
 Ideally the  recipients should be within 15 kg of their ideal body 
weight 
 Recurrent or persistent pulmonary infections -  contraindication to 
Single lung transplantation.  
Other considerations : 
 Previous thoracic surgery increases the risk of haemorrhage 
 Cor pulmonale is not a contraindication to single lung 
transplantation 
 Psychological stability is necessary 
 Abscence of other major organ dysfunction should be confirmed. 
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Lung volume reduction surgery 
The rationale for this technique is to reduce the volume of over 
inflated emphysematous lung by 20 to 30%  with the aim of improving 
the elastic recoiling  of the lungs, diaphragm dynamic ability , chest wall 
mechanics and gas exchangeThe technique is usually performed via a 
median sternotomy, without the need for cardiopulmonary bypass. 
Careful selection is necessary on the basis of a distended thorax, 
predominantly upper lobe disease and severe functional disability despite 
a programme of pulmonary rehabilitation. The improvements that have 
occuered upto 6 months after surgery are better than conventional 
medical treatment with bronchodilators and corticosteroids. 
Thoracoscopic  laser  pneumoplasty has been developed as an 
alternative to the more  conventional excisional surgery.  The Nd: Yag 
laser appears to be a safer technique than Co2 laser. It relies on the fact 
that at operation the lung that remains represents the most affected areas 
and would absorb most energy; thus scarring and contraction would be 
concentrated at these sites. COPD & its complication are related to the 
chronic history. Management of exacerbations requires ventilator support 
with controlled oxygen therapy with or without assisted ventilation. Non 
invasive ventilation is the preferred form. 
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THYROID DISORDER 
History 
“Hypothyroidism was described for the first time in London 
(1870)”. It was named Myxedema. In 1888. It was found out  that 
cretinism,  Myxedema & Post Thyroidectomy changes were a result of 
loss of function of thyroid gland. Kendall isolated Thyroxin hormone  in 
1914. Harrington synthesized “Thyroxine” in 1926. However; synthesis 
of Thyroxine was done in large scale in 1949. Later it became a 
universally accepted therapy for hypothyroidism. 
THYROID GLAND  
 Anatomy of Thyroid Gland 
Thyroid gland has a midline isthmus lying horizontally just below 
the Cricoid Cartilages Right & left lateral lobes that extend superiorly 
together, in front of neck giving the appearance of butterfly. The gland is 
enclosed by pre tracheal fascia  under the strap neck muscles which 
makes the gland move up with the  deglutition. 
Histology of Thyroid  
 Thyroid gland is divided by thin fibrous septa into Pseudolobules. 
These pseudolobules are composed of follicles or acini which  are 
densely surrounded by  capillary networks. Follicular walls are lined  by 
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cuboidal epithelium.  Protenaceous colloidal material  filled within the 
lumen of follicles called as Thyroglobulin. The peptide sequences of T4 
and T3 are stored and synthesized as component of Thyroglobulin. 
Embryology  of Thyroid Gland  
Develops from the ectoderm of the pharyngeal floor  with some 
contribution from the lateal pharyngeal pouches. Thyroglossal duct, 
which extends from the foramen caecum near the base of the tongue to 
the isthmus of the thyroid arise as  descent of the midline thyroid anlagen. 
The posterior aspect of the thyroid gland becomes associated with the 
parathyroid gland & the para follicular C cells  during the development, 
which are derived from ultimo-bronchial body, which become 
incorporated into its substance · While they undergo malignant 
transformation, the C cells are the source of the calcitonin & leads  to 
medullary thyroid carcinoma. At about 10-12 weeks of gestation, the 
foetal thyroid begins to concentrate & organify Iodine. Maternal TSH and 
T4 do not cross the placenta, but the maternal TRH crosses the placenta. 
The major source of thyroid hormone in the foetal life is T4 from the 
foetal thyroid itself. · The functional unit is foetal pituitary – thyroid axis 
which is distinct from that of mother. 
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Physiology of Thyroid Gland  
“Thyroid secretes hormones – Thyroxin (T4), Triiodothyronine (T3) & 
Calcitionin”. Thyroid follicles secretes only the first two hormones & 
termed as  “Thyroid Hormones”.  Calcitonin is chemically & biologically 
different, secreted from parafollicular C cells. It regulates calcium 
metabolism along with Parathorrmone (PTH). Iodine enters the thyroid in 
the form of inorganic or organic iodide which  is oxidized by peroxidise 
enzyme. Subsequent reactions results in formation of thyroxin. The only 
source of T4 is thyroid gland. Thyroid secretes 20% of T3; extra 
glandular tissues produce the remaining amount by  peripheral conversion 
of T4 into T3. 
CHEMISTRY AND SYNTHESIS OF THYROID HORMONE  
Both T4 and T3 are product of 2 molecules of tyrosine with  iodine 
containing derivatives of  Thyronine. Thyroxine  (T4) - 3, 5, 3‟, 5‟ – 
Tetraiodothyronine  T3 - 3, 5, 3‟ – Triiodothyronine. Thyroid hormones 
are synthesized & stored in thyroid follicules as part of Thyroglobulin 
molecules, a glycoprotein synthesized in thyroid cells.  There are 5 steps 
in synthesis of thyroid hormones. 
1. IODIDE UPTAKE / IODIDE TRAPPING:  Iodine from peripheral 
circulation is taken into follicles by active transport Na + I – symporter. 
Iodine content of follicle regulates the iodide trap. Meagre storage 
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activates & large storage inhibits this trap. This process is mediated by 
TSH.  “Percholarate, Thiocyanates, Nitrates inhibits this trapping”. 
2. OXIDATION AND IODINATION :  Iodide trapped by follicular 
cells is transported by active transporter across the apical membrane by 
“Pendrin” & oxidized by thyroid peroxidise enzyme in the follicular 
membranes & forms Iodinium ions (I+) or hypoiodous acid (HOI) or 
enzyme linked hypoiodate (E-OI) with the help of H2O2. These various 
forms of iodine bind with Thyroglobulin and forms Monoiodothyrosine 
(MIT) and Diiodotyrosine (DIT). 
3. COUPLING : Pairs of iodinated tyrosine residues forms T3 and T4 by 
coupling.  Coupling is a oxidative reaction which is  catalysed by the 
same thyroid peroxidise.  TSH regulates this coupling process as well. 
4. STORAGE AND RELEASE : Tyrosine residues are stored as 
Colloids. These are taken back into follicular cells by Endocytosis which 
undergo lysosomal proteolysis then  released as T4 and T3. At rest, 
follicles filled with colloids are flat / cuboidal cells where TSH stimulated 
follicles are filled with columnar cells with lack of  colloids. 
5. PERIPHERAL COVERSION OF T4 TO T3 : Conversion occurs  in 
kidney &  liver. One third of T4 undergoes conversion & most of T3 in 
plasma is derived from liver. Target organs take up T3 for metabolic 
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functions except brain & pituitary which take up as T4 and converts in to 
T3 by their own cellular mechanisms. 
Relation between T3 and T4  
Physiologically Thyroid secretes higher amont of T4 comperd to 
T3.  Normally T4 is the major circulating form as it bound with plasma 
proteins 15 times more. T3 is five times more potent than T4. “T3 acts 
very faster than T4”. ·Peak effect of T3 comes earlier (1-2 days) whereas 
peak effect of T4 comes later (6-8 days).· T3 is more tightly bound to the 
nuclear receptors than T4. About one third of T4 is converted  to T3 in 
peripheral tissues,  liver and kidney, by D1 type of 5‟ Deiodinase (D1 
type 5‟ DI) and  released in to circulation. T3 is also generated within the 
cells like skeletal muscles, brain, pituitary and heart, by another enzyme 
type called type 2 deiodinase (D2 type 5‟ DI). T4 is converted  to 
metabolically active T3 or inactive reverse T3 (r T3). T4 & T3 are 
metabolized in liver by conjugation with Glucuronate and Sulfate. 
Enzyme inducers such as Phenobarbitone, Carbamazepine & phenytoin 
increase the metabolic clearance of the hormones without decreasing the 
proportion of free hormones in the circulation. Finally, T3 is an active 
form. T4 is a transport form ie .precursor of T3. Normal daily secretion of 
T3 – 10 - 30 mcgm. T4- 60-90 mcgm. T3 and T4 bound with 3 plasma 
proteins –  Thyroxin binding globulin (TBG) & Thyroxin binding pre 
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albumin (Transthyretin) & Albumin.  Plasma t ½ of T3 is 1-2 days; of T4 
is 6-7 days. The half life is increased in hypothyroidism and shortened in 
hyperthyroidism due to enhanced and blunted metabolism respectively. 
Only source of T4 is Thyroid gland 
Clinical Scenarios  with altered concentration of TBG  
INCREASED TBG           DECREASED TBG 
1. New born                             1.  Phenytoin 
2. OCP / Estrogens / Tamoxifen    2.  Acromegaly 
3. Biliary cirrhosis                  3.  Androgens 
4.  Chronic Active hepatitis        4.   Nephrotic syndrome 
5. Acute Intermittent Porphyria   5 Large doses of  glucocorticoids 
6. Pregnancy       6.  Chronic liver disease 
REGULATION OF THYROXIN SECRETION 
Thyroid hormone secretion is regulated by Hypothalamo - Pituitary 
– Thyroid axis. Thyrotropin releasing hormone (TRH) from 
hypothalamus stimulates anterior pituitary to secrete TSH,  this in turn 
stimulates thyroid gland as a result thyroxin is released from thyroid 
follicles. T3 & T4 are then released into circulation. T3 and T4 by the 
negative feedback mechanism directly control both hypothalamus and 
anterior pituitary. 
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Thyrotropin   Releasing   Hormone  
TRH is a  major positive regulator for pituitary TSH synthesis and 
release.  TRH production starts in fetus as early as 30 days of the IUF  .It 
undergoes rapid degradation in the serum. It reaches pituitary by a 
pathway consisting of TRH fibres that enter median eminence & release 
TRH into portal system. TRH also reach pituitary by direct diffusion from 
hypothalamus or through cerebrospinal fluid via  sub arachnoid process. 
The Anterior Pituitary 
Anterior lobe contain active cells that produce TSH. TSH cells are 
part of the lineage that is dependent on home box transcription factor pit 
– 12. Fetal pituitary TSH synthesis can be detected by 13 weeks but 
remain low till 18 weeks,  then it increases dramatically  in pituitary & in 
serum.  This is followed by increase in the serum total and free T4 levels. 
TSH Action  
TSH regulates thyroid gland function through TSH-R, a seven 
transmembrane G protein – coupled receptor (GPCR). The TSH – R is  
coupled to the sub unit of  Stimulatory G protein (G), activates adenylyl 
cyclise, leading to increased production of C - AMP. “TSH also 
stimulates phosphatidylinositol turnover by activating phospholipase C. 
The functional role of TSH – R is exemplified by consequences of 
naturally occurring mutations. Recessive loss – of – function mutations 
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cause congenital hypothyroidism and thyroid hypoplasia”. Dominant gain 
of function mutations cause sporadic or familial hyperthyroidism that is 
characterized by hyperthyroidism that is characterized by thyroid cell 
hyperplasia, goitre & autonomous function. This mimics the changes 
induced by TSH covalent binding or the interactions with thyroid-
stimulating immounglobulin (TSI) in Grave‟s disease. Activating TSH-R 
mutations occur as somatic events, leading to clonal selection and 
expansion of the affected thyroid follicular cell and autonomously 
functioning thyroid nodules. Although TSH is the dominant hormonal 
regulator of thyroid gland growth and function, many growth factors, 
secreted in the thyroid gland regulates the synthesis of thyroid hormone. 
They are endothelia, transforming growth factor (TGF), epidermal growth 
factor and insulinlike growth factor I (IGF-1). The quantitative roles of 
these factors are not well understood, but they are important in selected 
disease states. “In Acromegaly, increased  levels of growth hormone and 
IGF-1 are associated with goiter and predisposition to Multinodular 
Goiter (MG)”. Certain interleukins (ILs) & cytokines produced in 
association with autoimmune thyroid disease induce thyroid growth, 
whereas others lead to apoptosis. Iodine deficiency upregulates the NIS. 
It increases blood flow to thyroid and iodine uptake. Transient inhibition 
of thyroid iodide organification, by excess iodide itself is called Wolff-
Chaikoff effect. In individuals with normal thyroid, Iodide organification 
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resumes and the gland escapes from this inhibitory effect; the suppressive 
action of high iodide may persist in patients with underlying autoimmune 
thyroid disease. 
CAUSES OF HYPOTHYROIDISM 
Primary  
 Subtotal or Total Thyroidectomy,  
 Iatrogenic - External beam radiotherapy for Hodgkin‟s lymphoma.  
 Congential Hypothyroidism: TSHR mutation, Dyshormonogenesis,  
Aplasia or ectopic thyroid gland.   
 Infiltrative disorders like sarcoidosis, scleroderma, cystinosis, 
amyloidosis, hemochromatosis & Reidel‟s thyroiditis.   
 Autoimmune hypothyroidism: atrophic thyroiditis, Hashimoto‟s 
thyroiditis.   
 Drugs : Sunitinib, Iodine excess (including iodine – containing 
contrast media & Amiodarone), Antithyroid drugs, Interferon, 
Cytotoxics , Aminoglutethimide, Lithium and P-AminoSalicylic 
acid, Deficiency of iodine. 
Transient  
 Withdrawal of Thyroxine treatment 
 Post treatment or Subtotal Thyroidectomy for Graves‟ disease 
 Subacute Thyroiditis 
 Silent Thyroiditis   including Postpartum Thyroiditis 
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Secondary  
Hypothalamic disease : Infiltrative disorders, tumors, trauma, 
idiopathic. 
Hypopituitarism:-   Tumors, pituitary surgery / irradiation /  
infiltrative disorders. Isolated TSH deficiency, Genetic forms of 
combined pituitary hormone deficiencies Sheehan‟s syndrome, trauma  
Dexarotene treatment. 
CLINICAL PRESENTATION OF HYPOTHYROID DISORDERS: 
Symptoms 
 Fatigue , lethargy, Dry skin , Tiredness, Weakness, Lastittude, 
Hair loss& Constipation 
Signs  
Puffiness of face, hands & feet,   Diffuse alopecia, 
PseudoMyotonic reflexes, Weight gain with poor appetite,  Dry coarse 
skin; Cold  extremities,  Serous  effusions,  Difficulty in concentrating 
and poor memory,  Dyspnoea,  Peripheral edema,  Bradycardia,  
Menorrhagia, Hoarseness,  Carpal tunnel syndrome. 
Clinical Examination  
Examination is normal in most of the hypothyroids. Some patients 
have  clinical signs such as typical hypothyroid facies suggestive of overt 
hypothyroidism. Skin  may be  cold, dry, rough & scaly. Peripheral 
edema of feet and hand typically non pitting in nature. Nails may be 
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brittle and thickened. Some patients  have Madarosis (loss of hair in the 
lateral third of the eyebrows). Patients may have sinus bradycardia with  
diastolic hypertension. Blood pressure may be normal (or) low in 
subclinical hypothyroidism. The thyroid gland may be rubbery, enlarged 
& firm. It is non-tender, commonly no bruit is heard. Thyroid may be 
normal in size also. Patients can have memory loss & slow speech. A 
polyneuropathy like carpel tunnel syndrome with involvement of some 
peripheral nerves in form of  parasthesia may be seen. 
LABORATORY DIAGNOSTIC EVALUATION 
Measurement of Thyroid Hormones 
“TSH levels changes dynamically in response to alterations of T4 
and T3. First approach to thyroid testing is to first find out whether TSH 
is normal, suppressed or elevated”. In  rare exceptions, a normal TSH 
level excludes a primary thyroid dysfunction. The enhanced sensitivity & 
specificity of TSH assays have greatly improved laboratory assessment of 
thyroid function. Immune chemi-luminometric assays - ICMAs for TSH 
are sensitive enough to identify between the suppressed values that occur 
with Thyrotoxicosis and with the lower limit of the reference ranges. 
Extremely sensitive  -fourth generation assays can detect low  TSH levels 
(0.004 mU/L). The TRH stimulation test is now obsolete because of the 
widespread availability of the TSH ICMA. Also there is often a failure of 
47 
 
TSH to rise after an intravenous bolus of 200-400g TRH.  “The finding of 
an abnormal TSH level should then be followed by circulating thyroid 
hormone levels to correctly diagnose hypothyroidism (elevated TSH) or 
hyperthyroidism (Suppressed TSH)”. Radio immunoassays are widely 
available for serum totalT4 & totalT3. T4 and T3 are highly protein-
bound. Medications, illness, genetic factors Can influence protein 
binding. So  Free hormone levels which correspond to the biologically 
activity should be measured next. This is because total thyroid hormone 
level is not affected by changes in serum binding protein affinity. Serum 
TSH level is the first line of investigation in the diagnosis of primary 
hypothyroidism and hyperthyroidism. However the test is not diagnostic 
in secondary thyroid disorders.  
Thyroid hormones level in various clinical scenarios 
Condition Free T3 Free T4 TSH 
Subclinical 
Hypothyroidism 
Normal Normal Increased 
Subclinical 
Hyperthyroidism 
Normal Normal Low 
Primary 
Hyperthyroidism 
Increased Increased Undetectable 
Primary(overt) 
Hypothyroidism 
Low or Normal Low High 
48 
 
Condition Free T3 Free T4 TSH 
Secondary 
Hyperthyroidism 
Increased Increased 
Normal / 
Increased 
Secondary 
Hypothyroidism 
Low  or  Normal Low 
Low or 
Normal 
T3 Toxicosis Well Increased Normal Undetectable 
 
Drugs influencing metabolism and Thyroid hormone functions  
Metabolic Process Increased Decreased 
Binding Proteins Heroin, Estrogen, 
Clofibrate 
Androgens, 
Glucocorticoids, 
Phenytoin 
Carbamazepine 
T4 synthesis / release Iodine Lithium, Iodide 
T4 Metabolism Rifampicin  
TSH Secretion Amiodarone  Phenytoin, 
Glucocorticoids, 
Dopamine agonist 
 
THYROID HORMONE RESISTANCE  
This syndrome is characterized by elevated FT3, FT4 but with 
normal TSH level.  TSH responsiveness to TRH is normal. Patient may 
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have Goitre, Short stature,  mental retardation & ADHD in children . The 
differential diagnosis is TSH secreting pituitary tumour. Treatment is by 
suppressing TSH with Bromocriptine, DT4, Tri iodo-thyroacetic acid & 
Octreotide. Thyroid ablation by either radioiodine or surgery is tried in  
refractory cases. 
SCREENING RECOMMENDATIONS FOR THYROID 
DISORDERS 
 Annual TFT for diabetic patients, 
 Type 1 DM women in first trimester of pregnancy &  post delivery, 
 Patients with hyperlipidaemia, 
 Monthly assessment in patients on Amiodarone & lithium 
 History of post partum thyroiditis, 
 Atrial fibrillation patients,  
 Annual TFT in Turner‟ Syndrome, Down‟s syndrome, Addison‟s 
disease, because of high prevalence of hypothyroidism.  
ATYPICAL THYROID FUNCTION TESTS 
TEST CAUSE 
Detectable TSH, Elevated FT3,FT4 
Heterophile Antibodies, TSH 
secreting pituitary tumor, Thyroid 
Hormone Resistence 
Low FT3, Elevated FT4 Amiodarone 
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TEST CAUSE 
Normal FT4, Suppressed TSH T3 Toxicosis 
Suppressed TSH, Normal FT3,FT4 
Excess Thyroxine Replacement 
Subclinical Thyrotoxicosis 
Sick  Euthyroid, 
 
SICK EUTHYROID SYNDROME / NON THYROIDAL ILLNESS 
SYNDROME (NTIS) 
  Low T4 and T3 with normal (or) low TSH . Low concentration of 
thyroid hormones in all tissues. Found in  starvation, severe systemic 
illness, cardiac failure, liver failure, infections, malignancy, adrenal 
hypofunction. Benefit of thyroxine replacement is controversial . 
Treatment – manage the underlying illness. 
ATYPICAL CLINICAL SITUATION  
Struma Ovarii 
 Ovarian Teratoma with hyperfunctioning Thyroid tissue. There is no 
thyroid enlargement. Diagnosed by  Radioiodine Scan. 
Thyrotoxicosis Factitia  
Without thyroid enlargement, increased  FT4, low TSH, decreased 
uptake in scintigraphy.  Differentiated from thyroditis,   by TBG -  
Thyroglobulin level which is low. 
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Choriocarcinoma of Testes  
Associated with Thyrotoxicosis & Gynaecomastia – Elevated 
HCG. 
Transient Hyperthyroidism of Hyperemesis Gravidarum 
Increased beta HCG level is the most accepted mechanism. LH, 
FSH, TSH and beta HCH are glycoprotein hormones. It contains a 
specific beta subnit with a common alpha subunit. TSH level is decreased 
& serum free T4 raised. TFT returns to normal after recovery from 
hyperemesis gravidarum. Anti thyroid drugs are not needed. 
Trophoblastic Tumours  
Theses tumours secrete HCG. HCG is structurally similar to TSH 
and eventually stimulates thyroid. So there may be mild Thyrotoxicosis. 
AMIODARONE AND THYROID FUNCTION  
Amiodarone - Benzofuronic derivative has structural similarity to 
thyroxin. High  iodine content is present in Amiodarone (39% by weight). 
Daily optimal intake of iodine is around 150 – 200 µgm/ day. But in 
Amiodarone dose 200 – 700 mg per day, 7-21 mg of  iodine enters the 
body. T 1/2 of Amiodarone is 52.6 + 23.7 days. Thyroid function 
abnormality occurs in 50% of patients of chronic Amiodarone intake. In 
areas with high iodine intake Amiodarone induced hypothyroidism (AIH) 
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manifest. Amiodarone Induced Thyrotoxicosis (AIT) occurs in areas with 
low iodine intake. AIT develops even after several months of 
discontinuation of Amiodarone owing to long half life. Hypothyroidism is 
common in females & in patients with positive thyroid auto antibodies. 
TFT should be done every 6 months in patients on Amiodarone therapy. 
Thyrotoxicosis due to iodine excess is AIT type I. Thyrotoxicosis due to 
toxic effect of Amiodarone is  AIT type II. 
Feature AIT Type I AIT Type II 
Etiology Iodine excess Thyroiditis 
Vascularity Normal / increased Decreased 
Goitre Frequent Infrequent 
Thyroid antibodies Positive Negative 
Late Hypothyroidism No Possible 
Thyroid clinical signs Present Absent 
IL 6 Normal Highly elevated 
Thyroglobulin 
Normal / Mild 
elevation 
Highly Elevated 
Radioiodine Uptake Normal Decreased 
 
SUBCLINICAL HYPOTHYROIDISM 
 TSH level is raised but free thyroid hormones are normal 
 Indication for treatment of Subclinical hypothyroidism  
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1. TSH level > 10, 
2. Thyroid auto antibodies high titre, 
3. Previous treatment of grave‟s disease / Radioiodine, 
4. Pregnancy,  
5. Dyslipidemia with CAD risk factors 
SUBCLINICAL HYPERTHYROIDISM 
Undetectable TSH level with normal levels of T3 & T4. It is 
Endogenous  with nodular thyroid disease or underlying Grave‟s disease 
and exogenous in over correction with levothyroxine. In endogenous type 
ocuuring in  elderly, Ablative therapy with radio-iodine is the best initial 
treatment. In exogenous type, dose of thyroxine has to be reduced except 
in those with prior thyroid malignancy in whom TSH suppression is 
mandatory. And if there is new onset cardiac failure, atrial fibrillation, 
angina, accelerated bone loss or borderline high serum T3 level is 
present, the dose of  levothyroxine(T4) must be reduced. 
THYROID AND PREGNANCY:  
TBG level is increased during pregnancy. Total T3 & TT4 levels 
may be raised but free hormone levels are normal. Trimester adjusted 
reference values has to be taken as normal referrences during pregnancy.  
The  FT4 index ( “Adjusted T4” ) can be taken as a reliable assay during 
gestational period. The non-pregnant  TT4 level (50-150 nmol/liter) can 
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be taken by multiplying this range by 1.5-fold in the second & the third 
trimesters of pregnancy. 
SCREENING FOR HYPOTHYROIDISM  
Various recommendations have been proposed. 
1.  American Thyroid Association( ATA): 
Men and women >35 years must be screened every 5 years 
2.  American Association of Clinical Endocrinologist : 
Women and older people should be screened. 
3.  American college of Obstetrics and Gynaecology : 
Women with autoimmune disease and family history of thyroid 
disease Screened at 19 years. 
4.  American college of Physicians(ACP): 
Symptomatic thyroid disease in Women > 50 years. 
5.  Royal college of Physicians : 
Healthy adult population is not justified 
6.  Indian Thyroid Society : 
Routine screening is not indicated. 
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SCREENING OF HIGH RISK POPULATION  
In the following subset of patients routine screening for thyroid 
dysfunction would be beneficial 
 Menstrual irregularities, 
 Infertility, 
 Dyslipidemia, 
 Unexplained Hyponatremia, 
 Type 1 diabetes, 
 Carpel tunnel syndrome, 
 Depression, 
 Short stature, 
 Recurrent abortion, 
 Down‟s syndrome, 
 Pregnancy, 
 Family history of thyroid disease, 
 Exposure to radiation. 
DIAGNOSIS OF THYROID DISORDER 
TSH estimation – an effective screening tool for  thyroid 
dysfunction. If TSH levels are elevated, T3/T4 estimation should be done. 
If T3/T4 levels are normal possibility of subclinical hypothyroidism 
should be considered . Free T3/T4 estimation are done to confirm the 
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diagnosis. Anti TPO antibodies (TPO) maybe done if Hashimoto 
Thyroiditis suspected. 
TREATMENT  
Treatment of all cases of subclinical hypothyroidism is not 
generally indicated.  
There are three principal reasons for starting therapy in subclinical 
hypothyroidism 
1.  To avert the symptoms of overt thyroid failure. 
2.  To reverse the effect of mild thyroid failure on various organ 
systems and relive subtle   signs and symptoms caused by mild 
thyroid failure 
3.  In specific situations like  
 Positive Anti Thyroid Antibodies, 
 Dyslipidemia, 
 Pregnancy, 
 Infertility, 
 Goitre, 
 Obesity, 
 Carpel tunnel syndrome, 
 Menstrual irregularities, 
 Unexplained Hyponatremia, 
 Short stature. 
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Dosage of thyroxin in overt hypothyroidism is 1.6- 1.8μg/kg/day, 
an initial dose of thyroxin of up 50-75μg per day is sufficient to bring the 
serum TSH level to normal in  subclinical hypothyroidism. A lower dose 
(12.5-25μg daily) is given to Ischemic Heart Diseased patients. After 4 – 
6 weeks of therapy, serum TSH is measured to see the response to 
treatment. It can be repeated  after dose adjustemnts. Once the levels 
become stable, TSH measurements are done every year . Thyroxine 
requirements increased  in pregnancy as there is a progressive thyroid 
failure and hence TSH has to be repeated at regular intervals & dosages 
are modified accordingly. 
GOALS OF THERAPY 
Goal is to keep the patient‟s thyroid profile in Euthyroid range with 
optimum dose of thyroxin supplementation. TSH level should be kept in 
the range of 0.5 to 5.0μIU/ml. In  pregnancy TSH should be <2.5μIU/ml. 
The patient should be followed up regularly till optimal control is 
achieved. If the patient had abnormal lipid profile before initiation of the 
treatment, repeat lipid profile once in 3 months till the biochemical 
parameters normalize. 
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COMPLICATIONS OF THERAPY: 
1. Osteoporosis  
Post-menopausal women are more prone to develop osteoporosis. 
It can be minimized by giving calcium supplements & encouraging 
calcium rich diet. 
2. Subclinical Hyperthyroidism 
It can be prevented by regular follow up with dose titration. 
Initially TSH should be repeated once in 6 weeks later once in 3 months. 
Once TSH levels  stabilizes, patient can be followed up once in 6 months 
and yearly thereafter. 
3. Overt manifestation of Ischemic Heart Disease 
In those patients with established coronary artery diseases is 
advisable to start with the lowest dose (12.5μ/day) followed by gradual 
titration according to TSH values. If high dose of thyroxin is initiated at 
the start of the therapy patient may present with ischemic symptoms. 
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MATERIALS & METHODOLOGY 
STUDY DESIGN: 
A Prospective Assessment Study Of Thyroid Dysfunction in 
Moderate to Severe COPD 
SETTING: 
One hundred  patients diagnosed previously as COPD, belonging 
to either sex  attending / admitted  in  Thoracic Medicine & General 
Medicine OPD/ Wards at Govt Rajaji Hospital, Madurai  was included as 
study population. 
COLLABORATING DEPARTMENTS:  
Department of  General Medicine, Department Of Thoracic 
Medicine, Department of Endocrinology, Department of Biochemistry, 
Government Rajaji Hospital, Madurai Medical College, Madurai 
SOURCE OF DATA: 
COPD patients attending / admitted in Thoracic Medicine & 
General Medicine OPD/ Wards during the period of September 2016 to 
November 2016 at Govt Rajaji Hospital, Madurai. 
SAMPLE SIZE: 
100  COPD  Patients 
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DURATION OF STUDY: 
3 Months  September 2016 – November 2016  
INCLUSION CRITERIA: 
One Hundred patients diagnosed as COPD as per GOLD – 
GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE 
PULMONARY DISEASE were included in the study population 
GOLD CLASSIFICATION OF COPD BY SPIROMETRY  
STAGES                       CHARCTERISTICS 
    (POST BRONCHODILATOR RESPONSE) 
Mild     FEV1 / FVC ≤ 70%, FEV1 > 80% 
Moderate    FEV1 / FVC ≤ 70%, FEV1 50-80% 
Severe    FEV1 / FVC ≤ 70%, FEV1 30-50% 
Very Severe    FEV1 < 30% PREDICTED (OR)                                              
     FEV1 <50% PREDICTED WITH  
     RESPIRATORY FAILURE    
EXCLUSION CRITERIA: 
 Known Hypothyroid & Hyperthyroid Patients 
 Patients Underwent Thyroid Surgery  
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 Patients On Medications That Interfere With TFT  - Amiodarone, 
Iodine         Preparations,  Immunosupressive Drugs 
 Patients Has Chronic Obstructive Disease Other Than COPD – 
Bronchiectasis, Cystic  Fibrosis. 
METHOD OF COLLECTING DATA 
“COPD patients of varying ages & sex  were selected carefully 
using GOLD criteria. Their written consent was taken. The history was 
elicited. Age, height, weight were recorded. Thorough clinical 
examination were carried out. The performance of the pulmonary 
function tests was demonstrated.”  Patients were made to undergo 
pulmonary function tests using  Medspiror, for 3 times at every 15 
minutes interval and best of 3readings was taken. The Forced Vital 
Capacity (FVC), Forced Expiratory Volume at the end of one second 
(FEV1),FEV1/ FVC ratio    were recorded. Patient belonging to Moderate 
& Severe COPD stages as per GOLD guidelines were included for the 
study. Then they were subjected for thyroid function test. 
CONSENT: 
Patients were informed about the details of the test performed and 
blood samples were collected with the consent. 
DATA COLLECTION: 
o Relevant History & Clinical Examination 
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 Age, sex, Height, Weight, BMI 
 Pulmonary Function Test By Spirometry  
 Thyroid Function Test – TSH, Free T4, Free T3, ( 
Chemiluminescence assay) 
 Arterial Blood Gas Analysis 
 Saturated Hb with O2  by Pulse oximeter 
 ECG 
 Chest Xray PA View 
INTERPRETATION OF RESULTS 
TSH   -   (0.3-5.5  µIu/ml) 
Free T4   -   (0.89 - 1.72ng/dl) 
Free T3                 -    (2.4-4.2pg/ml) 
      Thyroid hormones level in various clinical scenarios 
Condition Free T3 Free T4 TSH 
Subclinical 
Hypothyroidism 
Normal Normal Increased 
Subclinical 
Hyperthyroidism 
Normal Normal Low 
Primary 
Hyperthyroidism 
Increased Increased Undetectable 
Primary(overt) 
Hypothyroidism 
Low or Normal Low High 
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Condition Free T3 Free T4 TSH 
Secondary 
Hyperthyroidism 
Increased Increased 
Normal / 
Increased 
Secondary 
Hypothyroidism 
Low  or  Normal Low 
Low or 
Normal 
T3 Toxicosis Well Increased Normal Undetectable 
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STATISTICAL ANALYSIS 
Statistical analysis was done by using percentages, mean values, 
standard deviation, chi-square test, t-test and proportion test. A p-value 
<0.05 level was considered statistically significant and a p-value >0.05 
was considered as not statistically significant. 
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RESULTS & INTERPRETATION 
Table No: 1 Age Wise Distribution of Cases 
Age No Of Cases 
<40 9 
41-50 12 
51-60 25 
61-70 42 
>70 12 
Total 100 
 
 
In Our Study, Majority Of  Patients ( 42/100)  Were Within 60-70 
Yrs Of Age 
 
9 
12 
25 
42 
12 
0
5
10
15
20
25
30
35
40
45
 <  40  41 - 50  51 - 60  61 - 70  > 70
AGE DISTRIBUTION 
No.of cases
66 
 
 
Table No : 2   Sex Wise Distribution Of Cases 
Sex No  of  Cases 
Male 82 
Female 18 
 
 
In Our Study, Majority Of Study Population Were Males 
 (82/100) .  
 
 
82% 
18% 
SEX DISTRIBUTION 
Male Female
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Table 3:  Age Wise Distribution of Cases According  
To COPD Severity 
             Age     Moderate COPD     Severe COPD 
<40 5 4 
41-50 4 8 
51-60 19 6 
61-70 29 13 
>70 7 5 
Total 64 36 
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In Study Population, 
Patients Comes Under Moderate  COPD  Severity         -    64 
Patients Comes Under Severe  COPD  Severity               -     36  
Moderate COPD Severity Cases Predominatly                -     29 / 64 
Belong To  The Age Group    (60-70) 
Severe COPD Severity Cases Predominatly                   -     13/36  
Belong To The Age Group    (60-70) 
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Table No 4: Sex Wise Distribution Of Cases According  
To COPD  Severity 
Sex Moderate COPD Severe COPD 
Male 53 23 
Female 11 7 
Total 64 36 
 
 
In Study Population, 
Male Patients Belong To Moderate COPD  Severity         -   53 / 64 
Female Patients Belong To Moderate COPD Severity       -  11 / 64 
Male Patients Belong To  Severe COPD Severity              -   29 / 36 
Female Patients Belong To Severe COPD Severity            -   7 / 36 
Moderat
e
Severe
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70 
 
Table No 5: Mean Values of  FEV1 / FVC Ratio In Moderate &  
Severe COPD 
FEV1 / FVC 
COPD Mean SD P Value 
Moderate 61.59 5.98  
Severe 51.28 7.15 <0.001 sig 
 
 
In Study Population, 
Mean Values Of  FEV1/FVC Ratio In Moderate COPD  -  61.59 
Mean Values Of FEV1/FVC Ratio In Severe COPD        -  51.28 
P value  < 0.001 Which Is Significant   
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Table No 6: Mean Values Of  FEV1 In Moderate & Severe COPD 
FEV1 
COPD Mean SD P Value 
Moderate 62.5 7.55  
Severe 43.61 5.35 <0.001sig 
 
 
Mean Value OF FEV1 In Moderate COPD  -  62.5 ±7.5 
Mean Value OF FEV1 In Severe COPD     -   43.61±5.35 
P Value < 0.001 Which Is Significant 
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Table No : 7 Comparison Of TSH Mean Values In Study Population 
TSH 
COPD Mean SD P Value 
Moderate 9.27 2.35  
Severe 14.29 1.31 <0.001 sig 
 
 
Mean Value Of TSH In Moderate COPD   –   9.27 ±2.35 
Mean Value Of TSH In Severe COPD       –   14.29±1.31 
 (p value <0.001 Significant) 
Normal TSH -    (0.3-5.5   µIU/ML) 
TSH In Study population Is Above The Normal Range In Both Study 
Groups TSH Is Well Elevated In Severe COPD Compared To Moderate 
COPD Study Groups Which Clearly states That Hypothyroidism Is 
Marked As The Severity Of COPD Progress 
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Table No 8: Mean Values Of  Free T4 In Study Population 
Free T4 
COPD Mean SD P Value 
Moderate 0.64 0.36  
Severe 0.36 0.13 <0.001 sig 
              
 
Mean Value Of Free T4 In Moderate COPD   - 0.64±0.36 
Mean Value Of Free T4 In Severe COPD       - 0.36±0.13  
P value Is Significant <0.001 
Normal Free T4 Value - (0.89 - 1.72 ng/dl)  
As we Could Appreciate Free T4 Value Of Thyroid function Test Is Low 
In Both Study Groups Free T4 Is Well Markedly  Low In Severe COPD 
Compared To Moderate COPD Study Group 
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Table No : 9 Mean Value Of Free T3 In Study Population 
Free T3 
COPD Mean SD P Value 
Moderate 2.912 0.667  
Severe 2.161 0.768 <0.001 sig 
 
 
Mean Value Of Free T3 Among Moderate COPD  -  2.912 ± 0.667 
Mean Value Of Free T3 Among Severe COPD       -  2.161 ± 0.768 
Normal Free T3  -   (2.4-4.2pg/ml) 
In Our Study, Free T3 Values Were Comparatively Lower Limit Of 
Normal Range Among Severe COPD 
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Table No : 10 Biochemical Profile Of Thyroid Disorder In Study 
Population 
Clinical condition No of Cases 
Overt Hypothyroidism 53 
Subclinical 14 
Normal 33 
Total 100 
 
 
Biochemical Profile in Study Population  
Overt Hypothyroidism (TSH ↑, FT4 ↓ FT3 ↓ / ↔)    -   53  
Sub Clinical Hypothyroidism (Isolated TSH ↑ FT4 ↔FT3↔) - 14 
Normal Thyroid Function Profile                       - 33  
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Table No 11:  Biochemical Profile of Thyroid Disorder In Moderate 
& Severe COPD 
COPD 
Overt  
Hypothyroid  
Subclinical 
Hypothyroid 
Normal Total 
Moderate 28 11 25 64 
Severe 32 1 3 36 
Total 60 12 28 100 
 
 
Overt Hypothyroidism Among Moderate COPD               -     28 
Overt Hypothyroidism Among Severe COPD                    -     32 
Sub Clinical Hypothyoidism Among Moderate COPD      -    11 
Sub Clinical Hypothyroidism Among Severe COPD         -    1  
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Table No 12: Mean Value Of TSH In Thyroid Study Profile 
TSH 
COPD Mean SD P Value 
Overt & 
Subclinical 
Hypothyroid 
12.38 2.28  
Normal 7.75 2.62 <0.001 sig 
 
Mean TSH Value In Patients With Abnormal Thyroid Profile  
(Overt  & Sub clinical hypothyroidism)                                          - 12.38 
Mean TSH Value In Patient With Normal Thyroid Profile            -  7.75 
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Table No :13 Mean Value Of FreeT4 In Thyroid Study Profile 
Free T4 
COPD Mean SD P Value 
Overt & 
Subclinical 
Hypothyroid 
0.385 0.146  
Normal 0.935 0.25 <0.001 sig 
 
 
Mean Value of Free T4 In Study Group With Abnormal Thyroid Profile –0.385 
Mean Value of Free T4 In Study Group With Normal Thyroid Profile – 0.935 
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Table No  14:  Mean Value Of Free T3 In Thyroid Study Profile 
Free T3 
COPD Mean SD P Value 
Hypothyroid & 
Subclinical 
2.38 0.707  
Normal 3.314 0.563 <0.001 sig 
 
 
Mean Value of Free T3 In Study Group With Abnormal Thyroid Profile – 2.38 
Mean Value of Free T3 In Study Group With Normal Thyroid Profile    -  3.314 
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Table No : 15 Correlation coefficient among Thyroid Biochemical 
Parameters In  Our Study 
 
Correlation Coefficient 
 
TSH  VS  FT4 -0.757 very Good Correlation 
TSH  VS FT3 0.682 Good correlation 
 
Table No 16: Correlation Coefficient Betweeen COPD Parameter 
(FEV1) &  Thyroid Biochemical Parameters ( FT4, FT3) 
 
correlation coefficient 
 
FEV1  VS  TSH -0.72 Good Neg. correlation 
FEV1  VS  Free T4 0.649 Good correlation 
FEV1  VS  Free T3 0.474 Moderate correlation 
 
1.  Correlation Coefficient between FEV1 & TSH :   
Good Negative Correlation with statistical value :    
- 0.72 ( Good Negative Correlation) 
2. Correlation Coefficient between FEV1 & Free T4 :   
    Good Correlation with statistical value  : 
0.649 ( Good Positive Correlation) 
3. Correlation Coefficient between FEV1 & Free T3 : 
    Moderate Correlation with statistical value: 
  0.474 (Moderate Positive Correlation   
81 
 
Table No 17: Comparison Of Mean Values & Standard Deviation Of 
Various Parameters with  the  p Value & its significance 
Parameters 
Moderate 
COPD 
Mean 
Moderate 
COPD 
S.D 
Severe 
COPD 
Mean 
Severe 
COPD 
SD 
P Value 
pH 
(7.35-7.45) 
7.369 0.04 7.319 0.057 
<0.001 
sig 
SaO2 (95-
98%) 
93.37 2.49 88.86 3.86 
<0.001 
sig 
PCo2 (35-
45mmhg) 
44.7 4.49 51.5 6.19 
<0.001 
sig 
PO2 (85-
105mmhg) 
89.35 5.4 80.09 9.53 
<0.001 
sig 
HCO3 (22-
30 mEq/l) 
24.52 2.12 21.30 2.98 
<0.001 
sig 
 
SD – Standard Deviation   
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DISCUSSION 
COPD being a systemic illness, it doesn‟t affect only the lungs. 
COPD has varied systemic manifestations due to the chronic 
inflammatory mediators, Hypoxia , Hypercarbia & various  metabolic 
factors. Several systemic disorders can occur in the form of Anemia, 
Osteoporosis, Accelerated Ischemic Heart Disease, Muscle Wasting, 
Depression in COPD. COPD  also involves  the endocrine system 
particularly Thyroid in the form of Hypothyroidism has been shown in 
various studies in different countries. Hypothyroidism causes Inspiratory 
& Expiratory Muscle weakness due to impaired expression of myosin 
heavy chains IIb & decreased neuromuscular transmission. Severity of 
hypothyroidism linearly correlates with muscle weakness & myopathy. It 
also interfere with the respiratory drive, diaphragmatic function & 
alveolar ventilation adversely in COPD patients. All these factors results 
in frequent exaceberations of COPD & has significant contribution in 
affecting the quality of life of these individuals. 
In this Study, Majority of study population were Males (  n = 82) 
compared to female gender ( n = 18). Since Smoking is an important risk 
factor, COPD is quite common among males compared to female 
population.  
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In this study, Majority Of study group belong to the age group of 
60 – 70 years with accounting for about 42  of 100 COPD  patients. 
The prevalence of Abnormal Thyroid biochemical Profile in the 
study n =  67 out of one hundred COPD subjects.  Distribution of 
Abnormal Thyroid Biochemical Profile in form of Overt Hypothyroidism 
accounts for  53 % , subsequently Subclinical Hypothyroid profile ( 
Isolated TSH Elevation) accounts for about 14 %,  Subjects comes under 
Euthyroid state were 33 %. As such the study clearly depicts the 
prevalence of Thyroid dysfunction among COPD subjects were quite 
common ( n = 67%). This study shows consistency  with study published 
by Lalit Singh etal, in INTERNATIONAL JOURNAL OF 
CONTEMPORARY MEDICAL RESEARCH – 2016 conducted at UP 
2016;3(5):1239-1242. 
We  found a significant  Correlation  between TSH values  with the 
severity of COPD measured in terms of FEV 1.  Correlation coefficient 
between these two parameters was  (- 0.72)  Good Negative correlation. 
Thus this study shows that as the severity of COPD increases the 
incidence of  hypothyroidism also raises with corresponding elevation of 
TSH. Similar reports were shown by  Sevinc Sarinc Ulasli, Serife Sava 
Bozbas, Zeynep Erayman Ozen, Berna Akinci Ozyurek et al. Effect of 
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thyroid function on COPD exacerbation frequency: a preliminary study. 
Multidisciplinary Respiratory Medicine 2013;8:64. In their study.  
We found a significant relationship among Free thyroid hormone 
levels ( FT3, FT4) with the severity of COPD. As the numerical value of 
FEV1 drops down ( COPD progress to Moderate & Severe stages), the 
biochemical profile of Hypothyroidism manifest as Lower than the 
Normal Range of active thyroid hormone levels in the COPD subjects .  
Free T4 shows good correlation with mean among moderate COPD ( 0.64 
ng/dl) & then in Severe COPD Free T4 further lowers down with mean 
value of 0.36 ng/dl. 
Similarly Free T3 levels also shows significant relation with the 
FEV1 values of COPD severity. Mean free T3 among moderate COPD 
was found to be  2.912 pg/ml & severe COPD  as 2.161pg/ml. Similar 
reports were stated by  Gupta Madhuri, Vardey SK, Joshi Nalin, Dixit R. 
Evaluation of thyroid dysfunction in chronic obstructive pulmonary 
disease. Biomedical Research 2013;24:110- 113.  
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SUMMARY 
 
 100 COPD subjects admitted in the Govt Rajaji Hospital were 
study for  thyroid dysfunction during September – November 2016. 
 Age of the subjects varied from 40-80 years of age 
 Males were 82 , Females were 18. 
 Moderate COPD patients included in the study was 64, Severe 
COPD patients  in the study was 36. 
 Prevalence of Thyroid dysfunction in Moderate to Severe COPD 
subjects was 67 % of study population with Normal being 33% of 
study population 
 Overt Hypothyroidism contributes 53% of thyroid disorder in the 
study group, Subclinical Hypothyroidism contributes about 14% of 
thyroid disorder in the study.   
 Mean TSH value in Moderate COPD subjects  is 9.27±2.3 µIu/ml , 
Mean TSH value in Severe COPD subjects is 14.29±1.31 µIu/ml, P 
value of 0.001  which is of statistically significant. TSH showed 
Good Negative correlation ( - 0.72) with the COPD parameter 
FEV1 
 Mean free T 4 value in Moderate COPD subjects were 0.64±0.36 
ng/dl , Mean free T4 in Severe COPD subjects were 0.36 ±0.13 
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ng/dl. P value of statistically significant <0.001.  Free T4 parameter 
showed Good correlation with FEV1( 0.649). 
 Mean free T3 in Moderate COPD subjects were  2.912±0.667 
pg/ml, Mean free T3 in Severe COPD subjects were 2.161±0.768. 
p value of free T3 in the study is of <0.001 which proved to be 
statistically significant. Free T3 parameter showed Moderate 
correlation (0.474) with COPD parameter FEV1. 
 Several other parameters such as pH, Po2, Pco2, Sao2, Hco3  also 
showed statiscally significant relation with the COPD severity. 
 Thus from the study, we came to know that as the COPD 
individuals progress in the airflow limitation from mild to 
moderate & then to severe COPD stages , they encounter 
Hypothyroidism biochemical features of elevated TSH with Lower 
Values of FT3 & FT4 which remarkably affects the quality of life 
of COPD individuals .  
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LIMITATIONS OF THE STUDY 
 
 It is a single centre study so results are needed to be evaluated 
further. 
 We couldn‟t able to equalise the study subjects as Moderate COPD 
subjects were higher than the Severe COPD subjects. 
 Radionucleotide Scan  Of Thyroid Gland often  reveals the thyroid 
functionality quite accurate which was not included in the study. 
 Period of study is of short duration. 
 
 
 
 
 
 
 
 
 
 
 
88 
 
CONCLUSION 
 
COPD patients in their due course of the illness develop multiple 
systemic complications. Hypothyroidism is one among such systemic 
complications of COPD. As there is progressive airflow limitation , the 
severity of COPD progress which results in varied thyroid function 
abnormality particularly Hypothyroidism. Hypothyroidism has 
remarkable effects on the respiratory dynamics & mechanics of 
ventilation which culminating in frequent exacerbations  & respiratory 
failure. Thyroid dysfunction in COPD has important effects in affecting 
the quality of life & hospitalization in COPD individuals. Hence COPD 
patients should be regularly monitored for abnormal thyroid function & 
managed accordingly to improve their quality of life. 
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PROFORMA 
 
Name : 
Age  /  Sex :  
IP / OP Number : 
Occupation : 
Chief Complaints: 
History Of Presenting Complaints: 
Past History:  
       H/o DM, SHT,TB,BA,COPD,CAD,CVA,CKD,SEIZURES 
Personal History: 
         Number of Years Of Smoking Cigarettes / Beedi 
         Number Of Cigarettes / Beedi Smoked Per Day 
Clinical Examination: 
General Examination: 
       Pallor, Icterus, Cyanosis, Clubbing, Lymphadenopathy, Edema 
Vitals: 
 PR: 
BP: 
RR: 
SPO2: 
Temp: 
 
 
Systemic Examination: 
 RS: 
 CVS: 
 CNS: 
 PA: 
Laboratory Investigations: 
RBS, RFT, LFT. 
Complete Hemogram. 
Chest Xray PA View 
ECHO 
PULMONARY FUNCTION TESTS (Spirometry) 
FEV1 
FVC 
FEV1/FVC% 
THYROID FUNCTION TEST : 
TSH 
FREE T4 
FREE T3 
Saturated O2 by Pulse Oximetry 
ARTERIAL BLOOD GAS ANALYSIS 
          pH   
PO2 
PCO2 
HCO3 
 
 
MASTER  HART 
S. 
NO 
PATIENT 
FEV 1 
 
TSH 
FREE 
T4 
FREE T3 
HYPOTHY/
NORMAL 
 
MALE / 
FEMALE 
COPD 
SEVERITY    
1 M 57 MODERATE 9.5 0.46 2.1 HYPOTHY 
2 M 51 MODERATE 11.3 0.37 2.2 HYPOTHY 
3 M 30 SEVERE 13.7 0.22 1.9 HYPOTHY 
4 M 50 MODERATE 10.37 0.38 2.6 HYPOTHY 
5 M 74 MODERATE 8.92 0.62 2.1 HYPOTHY 
6 M 30 SEVERE 12.29 0.29 1.9 HYPOTHY 
7 M 78 MODERATE 4.48 1.13 2.9 NORMAL 
8 M 56 MODERATE 11.93 0.37 2.4 HYPOTHY 
9 M 57 MODERATE 9.98 0.57 2.06 HYPOTHY 
10 M 28 SEVERE 12.65 0.31 2.3 HYPOTHY 
11 F 73 MODERATE 8.54 0.58 2.24 HYPOTHY 
12 M 44 SEVERE 10.97 0.47 2.47 HYPOTHY 
13 M 69 MODERATE 8.83 0.91 2.43 SUB  HY 
14 M 67 MODERATE 5.43 1.24 3.32 NORMAL 
15 M 58 MODERATE 10.14 0.75 2.24 HYPOTHY 
16 M 77 MODERATE 9.92 0.9 2.48 SUB  HY 
17 M 48 SEVERE 10.97 0.66 2.4 HYPOTHY 
18 M 61 MODERATE 9.89 0.63 2.43 HYPOTHY 
19 F 70 MODERATE 8.88 0.67 2.4 HYPOTHY 
20 F 65 MODERATE 10.31 0.55 2.34 HYPOTHY 
21 M 47 SEVERE 9.83 0.37 1.96 HYPOTHY 
22 M 72 MODERATE 4.86 1.01 3.54 NORMAL 
23 F 48 SEVERE 11.01 0.33 1.9 HYPOTHY 
24 M 71 MODERATE 5.04 1.61 2.2 NORMAL 
25 M 67 MODERATE 7.79 1.02 2.5 SUB  HY 
26 M 70 MODERATE 9.93 1.7 3.9 SUB  HY 
27 F 61 MODERATE 4.87 1.41 3.87 NORMAL 
28 F 70 MODERATE 10.31 0.89 3.64 SUB  HY 
29 M 42 SEVERE 12.03 0.28 3.01 HYPOTHY 
30 M 47 SEVERE 11.98 0.47 2.01 HYPOTHY 
31 F 57 MODERATE 5.36 1.07 2.98 NORMAL 
 
 
32 M 44 SEVERE 10.68 0.33 2.01 HYPOTHY 
33 M 58 MODERATE 9.97 0.87 3.33 SUB  HY 
34 M 59 MODERATE 11.01 0.54 3.97 HYPOTHY 
35 M 70 MODERATE 8.14 0.67 3.87 HYPOTHY 
36 M 52 MODERATE 9.99 0.45 3.47 HYPOTHY 
37 M 71 MODERATE 8.82 0.35 2.22 HYPOTHY 
38 M 43 SEVERE 11.05 0.27 1.9 HYPOTHY 
39 M 66 MODERATE 7.61 0.68 2.24 HYPOTHY 
40 M 70 MODERATE 5.04 1.55 3.38 NORMAL 
41 F 72 MODERATE 4.63 1.47 3.87 NORMAL 
42 F 48 SEVERE 2.28 1.98 4.01 NORMAL 
43 M 44 SEVERE 9.81 0.52 3.88 HYPOTHY 
44 M 57 MODERATE 4.88 1.14 2.89 NORMAL 
45 M 44 SEVERE 11.38 0.28 1.78 HYPOTHY 
46 M 58 MODERATE 9.92 0.45 2.89 HYPOTHY 
47 F 44 SEVERE 10.08 0.4 2.24 HYPOTHY 
48 F 72 MODERATE 3.54 0.99 3.89 NORMAL 
49 M 66 MODERATE 4.48 0.92 3.87 NORMAL 
50 M 47 SEVERE 11.98 0.27 1.98 HYPOTHY 
51 M 66 MODERATE 8.13 0.51 2.4 HYPOTHY 
52 M 54 MODERATE 10.28 0.41 3.01 HYPOTHY 
53 M 68 MODERATE 3.88 1.08 3.36 NORMAL 
54 M 57 MODERATE 5.45 1.7 3.47 NORMAL 
55 M 41 SEVERE 11.78 0.33 2.04 HYPOTHY 
56 M 49 SEVERE 10.87 0.47 2.48 HYPOTHY 
57 M 63 MODERATE 8.98 0.8 2.83 SUB  HY 
58 M 48 SEVERE 2.85 1.57 3.34 NORMAL 
59 M 43 SEVERE 11.98 0.69 2.09 HYPOTHY 
60 M 61 MODERATE 9.07 0.33 1.97 HYPOTHY 
61 F 51 MODERATE 9.77 0.55 3.25 HYPOTHY 
62 M 68 MODERATE 9.04 1.03 3.07 SUB  HY 
63 M 66 MODERATE 9.99 0.38 3.06 HYPOTHY 
64 M 54 MODERATE 10.05 0.59 2.47 HYPOTHY 
65 M 68 MODERATE 11.07 0.91 2.85 SUB  HY 
66 M 41 SEVERE 10.66 0.44 2.47 HYPOTHY 
67 M 53 MODERATE 4.42 0.93 2.87 NORMAL 
 
 
68 M 56 MODERATE 3.88 1.08 2.78 NORMAL 
69 M 38 SEVERE 12.02 0.55 2.76 HYPOTHY 
70 M 47 SEVERE 12.08 0.28 1.18 HYPOTHY 
71 M 53 MODERATE 11.07 0.31 1.07 HYPOTHY 
72 F 67 MODERATE 5.07 1.01 2.99 NORMAL 
73 F 49 SEVERE 8.88 0.49 2.07 HYPOTHY 
74 M 62 MODERATE 12.03 0.91 2.48 SUB  HY 
75 M 42 SEVERE 12.22 0.34 2.39 HYPOTHY 
76 M 65 MODERATE 9.77 0.43 2.49 HYPOTHY 
77 M 69 MODERATE 4.48 1.35 3.97 NORMAL 
78 M 57 MODERATE 5.03 1.66 3.08 NORMAL 
79 F 40 SEVERE 14.49 0.22 1.01 HYPOTHY 
80 M 50 MODERATE 14.25 0.29 1.88 HYPOTHY 
81 M 58 MODERATE 5.08 1.77 4.45 NORMAL 
82 M 51 MODERATE 10.55 0.57 2.65 HYPOTHY 
83 M 63 MODERATE 5.45 1.7 3.6 NORMAL 
84 M 65 MODERATE 4.88 1.66 3.54 NORMAL 
85 M 46 SEVERE 15.57 0.24 0.98 HYPOTHY 
86 M 68 MODERATE 3.33 1.64 3.68 NORMAL 
87 M 47 SEVERE 12.37 0.97 3.27 SUB  HY 
88 M 58 MODERATE 11.07 0.31 1.99 HYPOTHY 
89 F 48 SEVERE 10.87 0.47 3.07 HYPOTHY 
90 M 69 MODERATE 11.99 1.02 2.88 SUB  HY 
91 M 42 SEVERE 14.37 0.22 1.04 HYPOTHY 
92 M 44 SEVERE 14.08 0.3 1.11 HYPOTHY 
93 F 48 SEVERE 10.34 0.33 2.07 HYPOTHY 
94 F 48 SEVERE 9.99 0.49 2.08 HYPOTHY 
95 M 50 SEVERE 11.07 0.54 2.11 HYPOTHY 
96 M 54 MODERATE 10.38 0.55 2.88 HYPOTHY 
97 M 42 SEVERE 14.88 0.23 1.08 HYPOTHY 
98 M 53 MODERATE 10.99 0.39 2.07 HYPOTHY 
99 M 39 SEVERE 16.87 0.17 0.99 HYPOTHY 
100 M 48 SEVERE 12.09 0.28 2.58 HYPOTHY 
 
 
 
 
ABBREVIATIONS 
 
COPD  - Chronic Obstructive Pulmonary Airway Disease 
FEV1  -  Forced Expiratory Volume at 1 (first)  second 
FVC   -  Forced Vital Capacity 
TSH   - Thyroid Stimulating Hormone 
FT3   -     Free Triiodo Thyronine 
FT4   -     Free Tetraiodo Thyronine  
GOLD   -   Global Initiative for Obstructive Lung disease  
TLC   -      Total Lung Capacity   
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